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Abstract
This study investigates the association between the treatment with hydroxychloroquine and mortality in patients admitted with 
COVID-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with COVID-19, admit-
ted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were 
extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with hydroxychloroquine, 
azithromycin, heparin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data 
on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting 
the data, 301 patients had died, 1449 had been discharged home from the hospitals, 240 were still admitted, and 85 had been 
transferred to hospitals not included in the study. Median follow-up time was 8 (IQR 5–12) days. Hydroxychloroquine had 
been used in 1857 patients. Hydroxychloroquine was associated with lower mortality when the model was adjusted for age 
and gender, with OR (95% CI): 0.44 (0.29–0.67). This association remained significant when saturation of oxygen < 90% 
and temperature > 37 °C were added to de model with OR 0.45 (0.30–0.68) p < 0.001, and also when all the other drugs, and 
time of admission, were included as covariates. The association between hydroxychloroquine and lower mortality observed 
in this study can be acknowledged by clinicians in hospitals and in the community. Randomized-controlled trials to assess 
the causal effects of hydroxychloroquine in different therapeutic regimes are required.
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Introduction
In December 2019, an outbreak of COVID-19, a novel 
disease caused by the virus SARS-CoV-2, was declared 
in China. In the first months of 2020, COVID-19 spread 
throughout the world [1, 2]. The number of new cases in 
some areas of the world is currently declining; however, it 
continues to rise worldwide with many countries having sec-
ond outbreaks [3]. It has been estimated that 80% of affected 
patients have mild symptoms, and in the rest, hospital care 
can be necessary, and mortality is less than 2% [2, 4, 5]. 
The large number of simultaneous cases of COVID-19 has 
overloaded hospitals in many countries, making it very dif-
ficult to provide an adequate care. Many governments have 
used costly and disruptive policies to confine and distance 
the population to reduce the transmission of the disease and 
prevent a second wave [5–7]. These measures will need to 
be maintained in some manner until vaccines or effective 
treatments become available to avoid the risk of later epi-
demics [5, 8]. COVID-19 is negatively affecting all areas of 
healthcare, and is also having an adverse impact on the entire 
society and the international economy.
Using limited evidence and clinical experience, doc-
tors have treated COVID-19 patients with different drugs 
to eliminate or reduce the presence of the virus, including 
hydroxychloroquine (HCQ) [9–12]. The use of this drug is 
 * Luis Ayerbe 
 l.garcia-morzon@qmul.ac.uk
1 Centre of Primary Care and Public Health Queen Mary 
University of London, 58 Turner Street, London E1 2AB, 
UK
2 Carnarvon Medical Centre, Southend-on-Sea, UK
3 Service of Internal Medicine. Hospital, Universitario HM 
Sanchinarro, Madrid, Spain
4 School of Population Health and Environmental Sciences, 
King’s College London, London, UK
5 National Institute for Health Research Biomedical Research 
Centre, Guy’s and St Thomas’ NHS Foundation Trust, 
London, UK
 Internal and Emergency Medicine
1 3
based on its anti-inflammatory and antiviral effect [11, 12]. 
There are some in vitro data supporting the ability of HCQ 
to inhibit SARS-CoV-2 activity [13, 14].
HCQ may lead to the clinical improvement of the 
patients, it is safe, economical, and easy to use, and it can 
be given both to admitted and outpatients. If the treatment 
with HCQ is confirmed to be effective, it could be used in 
the early stages of the disease, and decrease the need for 
admissions, the mortality, the transmission of the infection, 
and its impact on other areas of health care. However, the 
use of HCQ is supported by limited evidence, and it may 
not lead to any clinical benefit. Studies on the clinical out-
comes associated with HCQ are required. Research poli-
cies are currently shifting towards the investigation of more 
expensive treatments [15–18]. Studies on HCQ could inform 
evidence-based and affordable management for COVID-19, 
which may be particularly relevant when the world is facing 
an economic crisis, more so in areas where health care is 
based on limited resources.
This study investigates the association between treat-
ment with HCQ and mortality, in hospitalized patients with 
COVID-19.
Methods
The clinical records up to the 24th of April 2020, of all 
the patients with COVID-19 (n = 2075), admitted in all 17 
Spanish hospitals, of the private healthcare provider HM 
Hospitales, were reviewed. These hospitals are based in the 
provinces of Barcelona, Coruña, León, Madrid, Pontevedra, 
and Toledo [19]. Patients had been diagnosed with poly-
merase chain reaction test of respiratory samples for SARS-
CoV-2, between the 1st of March and the 20th of April 2020. 
Seven patients had been admitted before the 1st of March 
2020. Data on age and gender, together with temperature 
and saturation of oxygen at the time of admission, were 
collected. Data on treatments at any time during admission 
with HCQ were collected. Once it was approved for clinical 
use in COVID-19 patients, HCQ was started immediately 
after admission, and it was stopped if any abnormalities 
were identified in the ECGs that were done on a daily basis 
to patients who were taking it. HCQ was dosed as 400 mg 
twice daily the first day, followed by 200 mg twice daily for 
4–6 days. Data on treatments with azithromycin, steroids, 
heparin, tocilizumab, a combination of lopinavir with rito-
navir, and oseltamivir, were collected, as well. The limited 
evidence on which these treatments were based, and the rap-
idly evolving clinical protocols, resulted in these drugs being 
given in many different specific preparations, doses, and fre-
quency. No information on specific preparations of these 
drugs, dosage, duration of treatment, or route of administra-
tion, were collected. Finally, data on death were recorded.
The age of patients treated and not treated with HCQ was 
compared with t tests. The proportion of men and women 
for those treated and not treated with HCQ was compared 
with Chi-squared tests. The association between treatment 
with HCQ and mortality was examined with four different 
logistic regression models: model one was adjusted for age 
and gender; model two included age and gender, together 
with temperature > 37 °C, and saturation of oxygen < 90% 
on admission, which were both associated with mortality 
in an exploratory analysis; model three had all the variables 
previously mentioned together with treatment with azithro-
mycin, steroids, heparin, tocilizumab, a combination of lopi-
navir with ritonavir, and oseltamivir; finally, to account for 
the change in clinical management during the study period, 
model four was adjusted for all the previously mentioned 
demographic, clinical severity measures, and drugs, together 
with a categorical variable for date of admission (before the 
10th of March, 11–20th of March, 20–31st March, 1st–10th 
of April, and 11–20th of April). All covariates included in 
the four models were considered potential confounders. No 
further variables were included to avoid the complex inter-
pretation of results and collinearity. The software Stata 14.0 
was used for the analysis [20]. Missing data were treated as 
a separate category for temperature and oxygen saturation. 
Sensitivity analyses were made to compare estimates based 
on using missing data as categories with, (1) estimates based 
on complete data dropping variables with missing observa-
tions, and (2) complete case analysis; dropping cases with 
missing data.
Results
Among the 2075 patients whose records were reviewed, 
1256 were men, 819 were women, and the mean age was 
67.57. At the time of collecting the data, 301 had died, 1449 
patients had been discharged home from hospitals, 240 were 
still admitted, and 85 had been transferred to hospitals not 
included in the study. Median (IQR) follow-up time was 8 
(5–12) days. Data on treatment with HCQ were available for 
2019 patients. There was a younger age (p < 0.001), and a 
higher proportion of men (p = 0.017) for those who received 
HCQ. Among the 1857 patients who had been treated with 
HCQ, 237 had died. (Table 1).
HCQ was associated with lower mortality when the 
model was adjusted for age and gender with OR: 0.44 
(0.29–0.67), p value < 0.001. When the model was adjusted 
for age, gender, together with temperature > 37 °C and satu-
ration of oxygen < 90% on admission, and also when the 
model included all the previous variables plus treatment with 
all drugs, the association between use of HCQ and lower 
mortality remained significant. The analysis of interaction 
suggested that HCQ was associated with lower mortality, 
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and there was no difference for those taking (n = 1187), or 
not (n = 670), azithromycin, as well. In the final model where 
all the previous demographic, clinical variables, and drugs 
were introduced, together with time of admission, the asso-
ciation between treatment with HCQ and lower mortality 
was also significant. (Table 2).
Discussion
Treatment with HCQ was associated with lower mortality in 
patients admitted with COVID-19.
This study has strengths and limitations. Patients were 
not randomized and the differences in mortality may be 
explained by factors other than the use of HCQ. In an effort 
to control for the severity of disease, available markers were 
considered, and adjusted for, in all the models. The obser-
vation of a large number of unselected patients admitted 
in 17 hospitals, and the analyses run with some variations 
to test the consistency of the results are also strengths of 
this study. However, residual confounding is always pre-
sent in all observational research. The association, that was 
consistent across a set of models that adjusted for different 
potential confounders, provides support to an independent 
positive effect of HCQ. For all models, the sensitivity analy-
ses described in methods were used to assess the impact of 
missing data on the two markers of disease severity, and 
results were consistent with those presented.
HCQ has been used in all phases of COVID-19 since 
two studies, with no control arm and small sample size, 
published in March 2020, reported it to be associated with 
a reduction of the viral carriage and clinical improvement 
Table 1  Description of cohort N Age mean (SD) Female n (%) Death n (%)
Total cohort 2075 67.57 (15.52) 819 (39.47) 301 (14.51)
Oxygen saturation < 90%
 Yes 70 73.18 (13.97) 20 (28.57) 28 (40.00)
 No 221 67.00 (16.14) 95 (42.99) 24 (10.86)
Temperature > 37 °C
 Yes 159 61.20 (17.27) 47 (29.56) 24 (15.09)
 No 1422 68.53 (15.65) 577 (40.58) 197 (13.85)
Admission before 10th March 40 66.90 (16.57) 11 (27.50) 9(22.50)
Admission 10–19th March 412 64.73 (15.52) 156 (37.86) 82(19.90)
Admission 20–31st March 946 65.88 (14.63) 338 (35.73) 126(13.32)
Admission 1st–10th April 449 70.56 (16.78) 206 (45.88) 62(13.81)
Admission 11–20th April 228 73.93 (17.37) 108 (47.37) 22(9.65)
HCQ
 Yes 1857 67.11 (15.51) 705 (37.96) 237 (12.76)
 No 162 73.47 (16.22) 77 (47.53) 49 (30.25)
Azithromycin
 Yes 1223 68.33 (15.03) 456 (37.29) 146 (11.94)
 No 796 66.54 (16.52) 326 (40.95) 140 (17.59)
Steroids
 Yes 960 69.88 (14.01) 330 (34.38) 200 (20.83)
 No 1059 65.58 (16.76) 452 (42.68) 86 (8.12)
Heparin
 Yes 1734 68.59 (15.09) 686 (39.56) 242 (13.96)
 No 285 61.76 (17.67) 96 (33.68) 44 (15.44)
Tocilizumab
 Yes 421 66.19 (13.11) 117 (27.79) 89 (21.14)
 No 1598 68.00 (16.24) 665 (41.61) 197 (12.33)
Lopinavir + ritonavir
 Yes 1230 63.94 (14.28) 421 (34.23) 160 (13.01)
 No 789 73.37 (15.99) 361 (45.75) 126 (15.97)
Oseltamivir
 Yes 132 67.78 (13.79) 51 (38.64) 26 (19.70)
 No 1887 67.61 (15.78) 731 (38.74) 260 (13.78)
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[9, 10, 21]. This has allowed for its effects to be observed 
since then in a large number of different patients in many 
countries. Our results, showing that HCQ is associated with 
positive outcomes, are consistent with the ones first reported 
in March 2020. A number of observational studies later con-
ducted in China, France, Spain (in a hospital not included in 
our project), and the USA, have also reported the association 
between HCQ and lower mortality [22–27]. Three of these 
studies included over 2000 participants [23, 24, 26]. In one 
of these studies, only patients having mechanical ventilation 
were included [22]. In another one, HCQ was also associ-
ated with lower probability of admission to intensive care, 
shorter hospital admissions, and shorter duration of viral 
shedding [23]. In two of these studies, favourable results 
of HCQ combined with azithromycin were reported [23, 
24], and in another one, the lower mortality was observed 
for those on HCQ in combination with azithromycin and 
zinc [27]. The later study was based on primary care, and 
reported an association between treatment and lower rates 
of hospital admissions, as well. Another observational study 
conducted in primary care, were mortality was not the out-
come, showed significantly shorter time to clinical recovery 
for those treated with HCQ or HCQ plus azithromycin [28]. 
In our study, the addition of azithromycin to HCQ does not 
seem to add any clear benefit. A large multicentre observa-
tional study reported no association between HCQ, or HCQ 
with azithromycin, and lower mortality but significantly 
higher rates of discharge home were observed for patients 
treated by HCQ [29].
In a recent meta-analysis, studies were classified as big 
data, when electronic medical records had been used, or clin-
ical studies, when details of treatments were reported and the 
study had been conducted by the same physicians who cared 
for the patients. It reported, among clinical studies, an asso-
ciation of chloroquine derivates with clinical improvement, 
lower mortality, and viral carriage [30]. Finally, a small RCT 
reported the association of HCQ with shorter time both to 
clinical recovery and to reach viral RNA negativity [31].
The absence of any positive effects of the treatment 
with HCQ has also been reported. A number of observa-
tional studies have reported that HCQ, either alone or in 
combination with azithromycin, was not associated with 
lower mortality [32–35]. Three of these studies included 
over 1000 participants [32, 34, 35]. One of these studies 
included patients who needed oxygen [33] and another one 
used mortality or need for intubation as an outcome [34] 
Two RCTs have also reported no association between HCQ 
and survival [36, 37]. One of them also reported no benefit 
in need for admissions or clinical improvement [37]. The 
lack of clinical improvement was reported in another trial 
[38]. Finally, two more RCTs have reported no association 
between HCQ and virological clearance [39] or prevention 
of disease in individuals exposed to it [40]. A number of 
factors could explain the difference between our results and 
the ones observed in these studies [32–40] including the 
following: the clinical–epidemiological design of our work; 
[30] the involvement of all patients admitted with COVID-
19, regardless their past medical history, the time between 
onset of symptoms and the start of treatment, the duration of 
admission, and the need for oxygen; the different statistical 
approach; and the observation in our work of patients from 
private hospitals, who are likely to have a high socioeco-
nomic status [41]. The safety of the HCQ has been ques-
tioned, as it could negatively impact the immune response 
to the virus, or cause abnormalities in the ECG [33, 42, 
43]. However, none of the studies that we have reviewed, 
reporting no benefit on HCQ, show an increased mortality 
associated with it [32–40].
Further RCTs, observational studies, and summaries of 
both types of evidence to assess the associations between 
HCQ and survival are necessary. Future studies could also 
address at what dosage, and in what phase of the disease, 
does HCQ lead to the best possible outcome, for patients 
with different past medical histories [44]. The interven-
tional evidence on the management of COVID-19 is still 
limited. Therefore, clinicians could acknowledge the results 
presented in this study. The positive effect of HCQ seems 
consistent and its use could be considered in clinical set-
tings. HCQ is easy to administer, and its use in ambulatory 
patients, to reduce symptoms, prevent admissions, decrease 
mortality, and the transmission of the disease, could also be 
considered by clinicians and future researchers.
Table 2  Association between HCQ and mortality
Model 1 Adjusted for age and gender
Model 2 Adjusted for age, gender, temperature > 37  °C, and satura-
tion of oxygen < 90%
Model 3 Adjusted for age, gender, temperature > 37  °C, and satura-
tion of oxygen < 90% treatment with azithromycin, steroids, heparin, 
tocilizumab, a combination of lopinavir with ritonavir, and oseltami-
vir
Model 4 Adjusted for age, gender, temperature > 37  °C, and satura-
tion of oxygen < 90% treatment with azithromycin, steroids, heparin, 
tocilizumab, a combination of lopinavir with ritonavir, and oseltami-




Model 1 0.44 (0.29–0.67) < 0.001
Model 2 0.45 (0.30–0.68) < 0.001
Model 3 0.39 (0.24–0.64) < 0.001
Model 3 with a statistical interaction term for HCQ and azithromy-
cin
 1 Main effect HCQ 0.56(0.34–0.92) 0.022
 2 Main effect azithromycin 0.53(0.19–1.50) 0.233
 3 Interaction (1 and 2) 1.11(0.38–3.29) 0.846
Model 4 0.39 (0.24–0.64) < 0.001
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